Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner. Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
- Ponto de atenção: radiopharmaceutical.
- Ponto de atenção: benefit.
- Ponto de atenção: patients.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.
:quality(85)/f25244cd-734f-485a-80fb-56254b2f14e7.jpg)
